Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

Laurie S. Conklin; Bernard Cohen; Lindsay Wilson; Carmen Cuffari; Maria Oliva-Hemker

doi:10.1038/nrgastro.2010.7

Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

Laurie S. Conklin, Bernard Cohen, Lindsay Wilson, Carmen Cuffari, Maria Oliva-Hemker

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.Investigations. Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.Diagnosis. Anti-TNF-agent induced psoriasiform skin rash.Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.

Original language	English (US)
Pages (from-to)	174-177
Number of pages	4
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	7
Issue number	3
DOIs	https://doi.org/10.1038/nrgastro.2010.7
State	Published - Mar 2010

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1038/nrgastro.2010.7

Fingerprint Dive into the research topics of 'Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease'. Together they form a unique fingerprint.

Cite this

@article{1998746f9d7544c8aad94b1bd4cb32d3,

title = "Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease",

abstract = "Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.Investigations. Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.Diagnosis. Anti-TNF-agent induced psoriasiform skin rash.Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.",

author = "Conklin, {Laurie S.} and Bernard Cohen and Lindsay Wilson and Carmen Cuffari and Maria Oliva-Hemker",

year = "2010",

month = mar,

doi = "10.1038/nrgastro.2010.7",

language = "English (US)",

volume = "7",

pages = "174--177",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

AU - Conklin, Laurie S.

AU - Cohen, Bernard

AU - Wilson, Lindsay

AU - Cuffari, Carmen

AU - Oliva-Hemker, Maria

PY - 2010/3

Y1 - 2010/3

N2 - Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.Investigations. Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.Diagnosis. Anti-TNF-agent induced psoriasiform skin rash.Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.

AB - Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.Investigations. Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.Diagnosis. Anti-TNF-agent induced psoriasiform skin rash.Management. Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.

UR - http://www.scopus.com/inward/record.url?scp=77749254887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749254887&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2010.7

DO - 10.1038/nrgastro.2010.7

M3 - Article

C2 - 20203680

AN - SCOPUS:77749254887

VL - 7

SP - 174

EP - 177

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 3

ER -

Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this